Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy

by Fernando Concha-Benavente, Fernando Concha-Benavente, Robert L. Ferris, Robert L. Ferris
Published 2017-05-01

Human B Cells Mediate Innate Anti-Cancer Cytotoxicity Through Concurrent Engagement of Multiple TNF Superfamily Ligands

by Bratislav M. Janjic, Aditi Kulkarni, Aditi Kulkarni, Robert L. Ferris, Robert L. Ferris, Robert L. Ferris, Lazar Vujanovic, Lazar Vujanovic, Nikola L. Vujanovic, Nikola L. Vujanovic
Published 2022-03-01

Stereotactic Body Radiotherapy as Primary Treatment for Elderly Patients with Medically Inoperable Head and Neck Cancer

by John A. Vargo, Robert L. Ferris, Robert L. Ferris, David A. Clump, Dwight E. Heron, Dwight E. Heron
Published 2014-08-01

Stereotactic Ablative Radiosurgery for Locally-Advanced or Recurrent Skull Base Malignancies with Prior External Beam Radiation Therapy

by Karen Mann Xu, Kimmen eQuan, David Anthony Clump, Robert L Ferris, Robert L Ferris, Dwight E Heron, Dwight E Heron
Published 2015-03-01

Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response

by Margaret Folaron, Mihai Merzianu, Umamaheswar Duvvuri, Robert L. Ferris, Mukund Seshadri
Published 2019-07-01

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

by Zaima Mazorra, Anabel Lavastida, Fernando Concha-Benavente, Anet Valdés, Raghvendra M. Srivastava, Tatiana M. García-Bates, Esperanza Hechavarría, Zuyen González, Amnely González, Martha Lugiollo, Iván Cuevas, Carlos Frómeta, Braulio F. Mestre, Maria C. Barroso, Tania Crombet, Robert L. Ferris, Robert L. Ferris, Robert L. Ferris
Published 2017-06-01

Long-Term Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy for Recurrent, Previously-Irradiated Head and Neck Cancer

by Joel Thomas, Hong Wang, David A. Clump, David A. Clump, Robert L. Ferris, Robert L. Ferris, Umamaheswar Duvvuri, Umamaheswar Duvvuri, James Ohr, James Ohr, Dwight E. Heron, Dwight E. Heron, Dwight E. Heron
Published 2020-02-01

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action

by Wenwen Du, Min Yang, Abbey Turner, Chunling Xu, Robert L. Ferris, Jianan Huang, Lawrence P. Kane, Binfeng Lu
Published 2017-03-01

Neoadjuvant immunotherapy of locoregionally advanced solid tumors

by John Wright, Patrick M Forde, Robert L Ferris, Ahmad A Tarhini, Kathleen N Moore, Jennifer R Eads, Valerie Tatard-Leitman
Published 2022-08-01

Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer

by Andreas E. Albers, Xu Qian, Andreas M. Kaufmann, Daphne Mytilineos, Robert L. Ferris, Thomas K. Hoffmann, Albert B. DeLeo
Published 2018-07-01

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT

by Marie-Nicole Theodoraki, Saigopalakrishna Yerneni, William E. Gooding, James Ohr, David A. Clump, Julie E. Bauman, Robert L. Ferris, Theresa L. Whiteside
Published 2019-07-01

Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions.

by Erica C Nakajima, Charles Laymon, Matthew Oborski, Weizhou Hou, Lin Wang, Jennifer R Grandis, Robert L Ferris, James M Mountz, Bennett Van Houten
Published 2014-01-01

EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.

by Wenbo Ma, Fernando Concha-Benavente, Saskia J A M Santegoets, Marij J P Welters, Ilina Ehsan, Robert L Ferris, Sjoerd H van der Burg
Published 2018-01-01

Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma

by Masahiro Kikuchi, David A. Clump, Raghvendra M. Srivastava, Lingyi Sun, Dexing Zeng, Julio A. Diaz-Perez, Carolyn J. Anderson, W. Barry Edwards, Robert L. Ferris
Published 2017-07-01

The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018

by Paolo A. Ascierto, Lisa H. Butterfield, Sandra Demaria, Robert L. Ferris, Gordon J. Freeman, Roger S. Lo, Alberto Mantovani, Paul Nathan, Omid Hamid, Katerina Politi, Igor Puzanov
Published 2019-08-01

Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma

by Guilherme Rabinowits, Michael R. Migden, Todd E. Schlesinger, Robert L. Ferris, Morganna Freeman, Valerie Guild, Shlomo Koyfman, Anna C. Pavlick, Neil Swanson, Gregory T. Wolf, Scott M. Dinehart
Published 2021-12-01

T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response

by Benjamin A. Kansy, Gulidanna Shayan, Hyun-Bae Jie, Sandra P. Gibson, Yu L. Lei, Sven Brandau, Stephan Lang, Nicole C Schmitt, Fei Ding, Yan Lin, Robert L. Ferris
Published 2018-11-01

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule

by Jerome Galon, Sandra Demaria, Lisa H. Butterfield, Robert L. Ferris, Howard L. Kaufman, Willem W. Overwijk, Francesco M. Marincola, Pamela S. Ohashi, Ira Mellman, Pierre G. Coulie, Samir N. Khleif, Suzanne L. Topalian
Published 2016-11-01

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

by Ranee Mehra, Ina Rhee, Naiyer Rizvi, Robert L Ferris, Hussein Tawbi, Matthew D Hellmann, Sarah B Goldberg, Ryan J Sullivan, Helen X Chen, Jong Chul Park, Foluso O Ademuyiwa, Z Alexander Cao
Published 2023-03-01

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

by Julie E. Bauman, James Ohr, William E. Gooding, Robert L. Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T. Johnson, Adam C. Soloff, Gerald Wallweber, John Winslow, Autumn Gaither-Davis, Jennifer R. Grandis, Laura P. Stabile
Published 2020-06-01